Market Intelligence, Clinical Progress, and High-Purity Reagents for NK Cell-Targeting Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NCR3/NKp30/CD337 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NCR3/NKp30 ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1 EU/µg), HEK293 Expressed (Native Glycosylation), Sequence Verified. Ideal for SPR/BLI affinity screening. |
View NCR3 Products |
| Gene Delivery | NCR3/NKp30 Promise-ORF / Lentivirus Full-length human NCR3 ORF for stable cell line generation (NK-92 or reporter cell lines) to support functional assays. |
View NCR3 Products |
| Benchmark Ab | Anti-NCR3/NKp30 Recombinant Antibody Recombinant positive control antibody derived from clinical benchmark sequences for binding and activation assays. |
View NCR3 Products |
| Validator | NCR3/NKp30 siRNA Set Target-specific siRNA pool for target knockdown verification in primary NK cells or cell lines. |
View NCR3 Products |
| Related Target A | B7-H6 (NCR3LG1) The primary tumor-expressed ligand of NCR3. Essential for validating ligand-blocking or receptor-activation therapeutic modalities. |
View B7-H6 Products |
| Related Target B | BAG6 (BAT3) A soluble or membrane-bound ligand of NCR3 involved in NK cell activation and tumor immune evasion. Key for decoy receptor studies. |
View BAG6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species Cross-Reactivity (Human vs. Cynomolgus validation) | Human and Cynomolgus NCR3 ortholog proteins available with >95% purity and verified molecular weight. |
| Glycosylation-Dependent Ligand Binding (B7-H6 interaction) | HEK293 mammalian expression system preserves critical post-translational modifications (native N-glycosylation). |
| Lack of Validated Positive Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay standardization. |
| Off-Target Screening (NCR Family Cross-reactivity) | Homolog screening panels (NKp44, NKp46) strictly verified by mass spectrometry and SDS-PAGE. |
Live NCR3/NKp30/CD337 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NCR3 (NKp30) therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to multi-specific NK cell engagers (NKCEs) and CAR-NK cell therapies. As first-generation immunotherapies targeting T cells (like PD-1/CTLA-4) face resistance, the next wave of oncology R&D is targeting NK cell activation pathways to overcome the immunosuppressive tumor microenvironment.
NCR3 is a crucial activating receptor on natural killer cells. Therapeutic strategies aim to either engage NKp30 using bispecific/trispecific antibodies to bring NK cells into close proximity with B7-H6-expressing tumor cells, or to utilize NKp30-based chimeric antigen receptors (CARs) for cell therapy. Developing these complex modalities requires highly defined, glycosylated target proteins to accurately map binding kinetics and avoid off-target activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engager (NKCE) | Innate Pharma, Sanofi, Affimed | Solid Tumors, Hematological Malignancies | Dual-affinity validation (Need high-purity NCR3 and tumor-antigen proteins for bispecific binding kinetics) |
| CAR-NK / CAR-T | Academic institutions, Biotech startups | B7-H6 positive cancers, Neuroblastoma | Target density and specificity validation (Need NCR3 lentivirus for stable effector cell modeling) |
| Monoclonal / Bispecific Antibodies | Oncolyze, Genentech | Refractory Solid Tumors | Epitope mapping and species cross-reactivity (Need human and cynomolgus NCR3 recombinant proteins) |